Market Place
Sourcing Support
Virpax Closes $5M Public Offering of Common Stock and Warrants
15 Nov 2024 //
BUSINESSWIRE
Virpax Pharma Announces $5M Public Offering of Stock & Warrants
13 Nov 2024 //
BUSINESSWIRE
Virpax Pharma Reports Q2 2024 Results And Recent Developments
13 Aug 2024 //
BUSINESSWIRE
Virpax Pharmaceuticals To Present At Sidoti Virtual Investor Conference
08 Aug 2024 //
BUSINESSWIRE
Virpax Regains Compliance with Nasdaq Minimum Bid Price
24 Jul 2024 //
BUSINESSWIRE
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
10 Jul 2024 //
BUSINESSWIRE
Virpax Secures $2.5M Loan And Agreement For Potential Additional Funding
08 Jul 2024 //
BUSINESSWIRE
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
29 May 2024 //
BUSINESSWIRE
Virpax Announces Pricing of $2.25 Million Public Offering
15 May 2024 //
BUSINESSWIRE
Virpax Pharma Reports Q1 2024 Results, Recent Developments
13 May 2024 //
BUSINESSWIRE
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
30 Apr 2024 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2023 Year-End Results
26 Mar 2024 //
BUSINESSWIRE
Scilex Entered into a Agreement with Virpax Pharmaceuticals
15 Mar 2024 //
GLOBENEWSWIRE
Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics
27 Feb 2024 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance
27 Feb 2024 //
BUSINESSWIRE
Scilex Pharmaceuticals Enters into a Term Sheet with Virpax Pharmaceuticals
26 Feb 2024 //
GLOBENEWSWIRE
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study
07 Feb 2024 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
29 Dec 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces Leadership Transition
17 Nov 2023 //
BUSINESSWIRE
Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
17 Nov 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2023 Third Quarter Results
15 Nov 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial
31 Oct 2023 //
BUSINESSWIRE
Virpax Announces Extension of CRADA with Army Institute of Surgical Research
12 Oct 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
27 Sep 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
26 Sep 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
18 Sep 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Updates on Litigation
05 Sep 2023 //
BUSINESSWIRE
Virpax Pharma to Present at H.C. Wainwright 25th Annual Global Conference
28 Aug 2023 //
BUSINESSWIRE
Virpax Files Provisional Patent Application for NSAID Formulation and Method
10 Aug 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
24 Jul 2023 //
BUSINESSWIRE
Virpax Pharma Files Provisional Patent Application for Intranasal Delivery
13 Jul 2023 //
BUSINESSWIRE
Virpax Enters into CRADA with the National Advisory Neurological Disorder
21 Jun 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Announces CFO Transition
20 Jun 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference
13 Jun 2023 //
BUSINESSWIRE
Virpax Pharma Reports 2023 First Quarter Results and Recent Developments
12 May 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
10 May 2023 //
BUSINESSWIRE
Virpax Pharma Engages Dr. Pardeep Gupta to Assist in Development Probudur™
27 Apr 2023 //
BUSINESSWIRE
Virpax Reports on Progress of Envelta™
05 Apr 2023 //
BUSINESSWIRE
Virpax Announces Appointment of Barbara A. Ruskin to the Board of Directors
28 Mar 2023 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2022 Year-End Results
22 Mar 2023 //
BUSINESSWIRE
Virpax Announces Positive Preclinical Toxicology Results in Support of MET
13 Feb 2023 //
BUSINESSWIRE
Virpax Engages New England Investors to Direct Licensing Strategy for Envelta
31 Jan 2023 //
BUSINESSWIRE
Virpax to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
18 Jan 2023 //
BUSINESSWIRE
Virpax Engages Destum Partners to Direct Strategic Global Partnering Efforts
10 Jan 2023 //
BUSINESSWIRE
Virpax Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried for NobrXiol
04 Jan 2023 //
BUSINESSWIRE
Virpax Pharma Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
14 Dec 2022 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
09 Nov 2022 //
BUSINESSWIRE
Dr. Jeffrey Gudin, CMO of Virpax, to Present Poster at World Congress
24 Aug 2022 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2022 Second Quarter Results
15 Aug 2022 //
BUSINESSWIRE
Virpax Pursues OTC Medical Device Pathway for AnQlar
05 Jul 2022 //
BUSINESSWIRE
Virpax Will Pursue Direct to OTC Pathway for Epoladerm
27 Jun 2022 //
BUSINESSWIRE
Virpax Pharma to Present at H.C. Wainwright Global Investment Conference
19 May 2022 //
BUSINESSWIRE
Virpax Pharma Reports 2022 First Quarter Results and Recent Developments
16 May 2022 //
BUSINESSWIRE
Virpax Pharma Enters Into CRADA With U.S. Army Institute of Surgical Research
05 May 2022 //
BUSINESSWIRE
Virpax Selects Kindeva Drug Delivery as Development Partner
02 May 2022 //
CONTRACTPHARMA
Virpax Successfully Completes Initial Preclinical Studies for VRP324
26 Apr 2022 //
BUSINESSWIRE
Virpax Pharmaceuticals Reports 2021 Year-End Results
31 Mar 2022 //
BUSINESSWIRE
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm
22 Mar 2022 //
BUSINESSWIRE
Virpax Pharma Expands AnQlar Development and Commercialization Rights
15 Mar 2022 //
BUSINESSWIRE
Virpax Pharma has Potential Solutions for Opioid Crisis and COVID-19
15 Feb 2022 //
BUSINESSWIRE
